Commercializing Abysis - an integrated resource for storing and analyzing antibody sequence and structure

商业化 Abysis - 用于存储和分析抗体序列和结构的综合资源

• 批准号: BB/K015443/1
• 负责人: Andrew Martin
• 金额: $ 20.55万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FK015443%2F1
• 关键词: Commercializing; Abysis; integrated; resource; storing

Around 1/3rd of drugs in development are now monoclonal antibodies (mAbs) with >30 clinically approved. However many fail during development often because they create an immune reaction in the patient. Even newer 'fully human' mAbs can be immunogenic. We will enhance Abysis, our prototype software for storing and analyzing antibody sequence and structure, to allow wide used by pharmaceutical companies enabling production of better antibody-based biotherapeutics. The resource links DNA and protein sequence and structure to aid in developing therapeutic antibodies. We will enhance the interface and underlying code to make the system easier to maintain and install. The software will be modified to work more effectively with unusual antibodies from camel, llama, shark and chicken, which are now of interest to drug companies. We will link unusual sequence features to structure allowing identification of regions of antibodies that may be responsible for generating an immune response.

目前正在开发的药物中，约有三分之一是临床批准的单克隆抗体（mab）。然而，许多在发育过程中失败，通常是因为它们在患者体内产生了免疫反应。即使是较新的“完全人类”单克隆抗体也可能具有免疫原性。我们将加强Abysis，这是我们用于存储和分析抗体序列和结构的原型软件，允许制药公司广泛使用，从而生产更好的基于抗体的生物治疗药物。资源链接DNA和蛋白质的序列和结构，以帮助开发治疗性抗体。我们将加强界面和底层代码，使系统更容易维护和安装。该软件将被修改，以更有效地处理来自骆驼、美洲驼、鲨鱼和鸡肉的罕见抗体，这些抗体现在引起了制药公司的兴趣。我们将把不寻常的序列特征与结构联系起来，允许鉴定可能负责产生免疫反应的抗体区域。

项目成果

Viewing multiple sequence alignments with the JavaScript Sequence Alignment Viewer (JSAV).

• DOI: 10.12688/f1000research.5486.1
• 发表时间: 2014
• 期刊: F1000Research
• 作者: Martin AC